Axsome Therapeutics (AXSM) had its price target raised by UBS Group AG from $251.00 to $259.00. They now have a "buy" rating on the stock.
Is This Healthcare Stock a Millionaire Maker? [Globe and Mail, The (Toronto, Canada)]
Is This Healthcare Stock a Millionaire Maker? [Yahoo! Finance]
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions